Navigation Links
Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Date:8/19/2007

d a two-stage min-max design in which if there were at least nine responses in the first 42 patients, the trial was to continue to the second stage. On January 25, 2007, the Company announced that there had been at least nine remissions in the first stage and that the trial would therefore continue. Eighty-five patients were enrolled in order to ensure that at least 77 would be eligible for the trial and included in the full analysis set. At least 22 responses in 77 patients are required to confirm the 35% target response rate with 95% confidence. If the full analysis set includes all 85 patients, then at least 24 responses are required for confirmation of the target response rate.

Dr. Dan DeAngelo, Assistant Professor at Harvard Medical School and the Dana Farber Cancer Institute and an investigator on the trial commented, "The treatment of elderly patients with poor-risk AML represents a significant unmet medical need in clinical oncology, and it is important that we find new effective treatment options. Agents such as Cloretazine(R) (VNP40101M) have the potential to address this need."

Dr. Gary Schiller, Professor of Medicine at the UCLA Geffen School of Medicine and an investigator on the trial added, "This was a very important study for older AML patients treated here at UCLA. As a single agent therapy administered over 30 to 60 minutes, Cloretazine(R) (VNP40101M) is clearly an active agent with the potential to play an important role in the treatment of this difficult population."

On August 8, 2007, the Company announced that certain sites on the trial would remain open and continue to accrue patients to an ECG sub-study. Recent FDA/ICH guidance recommends that an electrocardiographic evaluation (QT/QTc) study be included in the clinical development of all new drugs. Normally these studies are conducted in healthy subjects so that disease factors/co- morbidities do not confound the results. As Cloretazine(R) (VNP40101M) is a cytotoxic agent w
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... N.J., May 1, 2015 Cambrex Corporation (NYSE: ... 31, 2015. Highlights , Sales ... increased 27% excluding foreign currency impact, driven by Innovator products ... from $8.4 million in the first quarter of 2014. ... $0.04 in the first quarter last year and Adjusted Diluted ...
(Date:4/30/2015)... , April 30, 2015  Accuray Incorporated ... has signed an agreement with MIM Software Inc. ... TomoTherapy ® and CyberKnife ® product portfolios. ... and MIM technology. This is Accuray,s second collaboration ... development of the first iPad-based treatment plan review ...
(Date:4/30/2015)... -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX ) announced today ... after the market closes on Thursday, May 7, 2015.  ... held on Thursday, May 7, 2015, at 4:30 p.m. ... participate in the call, please dial 877-303-1298 (for U.S. ... the teleconference will be available for one week and ...
Breaking Medicine Technology:Cambrex Reports First Quarter 2015 Financial Results 2Cambrex Reports First Quarter 2015 Financial Results 3Cambrex Reports First Quarter 2015 Financial Results 4Cambrex Reports First Quarter 2015 Financial Results 5Cambrex Reports First Quarter 2015 Financial Results 6Cambrex Reports First Quarter 2015 Financial Results 7Cambrex Reports First Quarter 2015 Financial Results 8Cambrex Reports First Quarter 2015 Financial Results 9Cambrex Reports First Quarter 2015 Financial Results 10Cambrex Reports First Quarter 2015 Financial Results 11Accuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software 2Accuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software 3Cumberland Pharmaceuticals To Announce First Quarter 2015 Financial Results 2
(Date:5/3/2015)... (PRWEB) May 03, 2015 Looking ... that will directly impact your career? The Master ... for dynamic leaders in multinational companies and for ... In a changing global landscape, differences in culture, ... relationships. The EMIB program develops the global competence ...
(Date:5/3/2015)... HealthPostures, a pioneering ergonomics company that ... the , May 5 - 7, 2015 Minnesota Safety ... the conference include its bestselling TaskMate sit stand solutions. ... 6100 TaskMate Executive. Features of the 6100 TaskMate Executive ... extended platform work surface and supply holders. Weighing 50 ...
(Date:5/2/2015)... 2015 “ ActOn ” was featured on ... look at the latest and coolest applications on the market ... AppWatch and technology expert, conducted the app review and shared ... with organizations to make a difference. , In this material ... things that aren’t about money, which is why those things ...
(Date:5/2/2015)... (PRWEB) May 02, 2015 “ Peachtree ... its monthly Tech Report, which features the latest and ... technology expert and special reporter for NewsWatch, conducted the ... high-end audio equipment. , Music is an important ... should be pampered and given the royal treatment. Peachtree ...
(Date:5/2/2015)... ZoomCare, the Portland-based innovator of on-demand healthcare announces ... new healthcare insurance to individuals and small businesses on ... is the nation’s first health insurance system built from ... Health Insurance was ZoomCare’s first such filing including rates ... review and regulation by the Oregon Insurance Division. Once ...
Breaking Medicine News(10 mins):Health News:The Saint Louis University's Master of International Business Is Now Enrolling For Fall 2015 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 3Health News:An Application to Help People Make a Difference Was Featured on NewsWatch Television 2Health News:Affordable High-End Audio Equipment was Featured on NewsWatch Television 2Health News:ZoomCare Applies to be on Oregon Exchange 2
... done on federal, state levels to combat tobacco use, ... Anti-tobacco campaigns registered some significant gains in 2007, with ... there,s still too little federal and state funding for ... their cigarette taxes. , That,s the conclusion of the ...
... David Schlotterbeck Named Vice Chairmen, DUBLIN, Ohio, Jan. ... services that improve the safety and,productivity of health care, ... of Teva North America, will join the company as,vice ... Supply Chain,Services sector., Barrett, 52, will join the ...
... With an eye to helping,customers improve their ... ) is now packing its Luxury and Ultra ... before., All Bragada Luxury mattresses will now ... the fabric. One of the softest fabrics,available for ...
... Her Battle ... with Hepatitis C, NEW YORK, Jan. ... advocating on behalf of,Americans with liver disease, is proud announce that it ... disease,including hepatitis C. To help spread the word about ALF,s work, EHE ...
... Compound Commonly Prescribed Hormone,Treatments, Use the Term "Bio-identical", ... a series of,warning letters to compounding pharmacies across ... asserted a policy that would deny hundreds of,thousands ... substituting its judgment for that of doctors. Wyeth,Pharmaceuticals, ...
... first Southern-style canned product ... American Heart Association, COLUMBUS, Ohio, Jan. 9 ... low fat and meatless, were the first,product line of ... savory,taste. Now, heart-healthy Sensibly Seasoned products also bear the ...
Cached Medicine News:Health News:Smoke-Free Workplace Laws, Cigarette Taxes on the Rise 2Health News:Smoke-Free Workplace Laws, Cigarette Taxes on the Rise 3Health News:Smoke-Free Workplace Laws, Cigarette Taxes on the Rise 4Health News:Cardinal Health Taps Teva Executive George Barrett to Lead Healthcare Supply Chain Services Sector 2Health News:Cardinal Health Taps Teva Executive George Barrett to Lead Healthcare Supply Chain Services Sector 3Health News:Bragada(R) Luxury Mattress, Inc. Upgrades Luxury and Ultra Luxury Collections 2Health News:EHE International Supports the American Liver Foundation's Efforts at Raising Awareness for Hepatitis 2Health News:FDA Asserts New Policy to Restrict Women's Access to Bioidentical Hormones 2Health News:Glory Foods Receives Heart Healthy Certification 2
... test system is intended for ... of VZ IgG antibody in ... fluorescent antibody (IFA) technique. The ... a recent infection or immune ...
... The Masimo SET LNOP Blue Sensor is ... babies. The LNOP Blue sensor is ... accuracy claims for cyanotic infants and children. ... presented challenging conditions for reliable and accurate ...
Inquire...
... Captia™ Varicella-Zoster Virus (VZV) IgG Enzyme-linked Immunosorbent ... and quantitative determination of IgG antibody to ... may be used for the determination of ... may be used to demonstrate seroconversion or ...
Medicine Products: